Infectious Disease

Latest News


CME Content


A 38-year-old man sought treatment for the intensely pruritic swellings that had arisen on his upper lip 2 weeks earlier. These sharply demarcated, tender, boggy, granulomatous pustular tumefactions are kerions.

Pompholyx in a Young Man

For as long as he could remember, a 27-year-old man had had a recurrent eruption on the palms and sides of the fingers. The rash was characterized by intense pruritus followed by the formation of small water blisters and increased perspiration that resolved with peeling of the skin. The dorsa of the hands were unaffected. Results of a potassium-hydroxide preparation and fungal culture of skin scrapings were negative for hyphae. The thyrotropin level was normal.

NEW ORLEANS -- For some physicians and nurses the decision to depart this city permanently is due to post-Katrina losses of practices, homes, and patients, but others cite discouragement and defeat at the failure of leadership that permeates the community.

WASHINGTON -- An empirical therapy used to battle the Spanish flu early in the 20th century may be a valuable addition if the 21st century avian flu turns into a pandemic, researchers here suggested.

WINNIPEG, Manitoba -- Canadians from coast to coast are remarkably prone to inflammatory bowel disease, possibly the result of a climate that discourages bacterial activity and promotes sterile conditions in childhood.

ROCHESTER, Minn. -- Most so-called post-polio syndrome may be the effect of muscle weakness that comes with age rather than an exacerbation of the disease decades later, according to researchers here.

TORONTO -- The bleak early days of the AIDS crisis, when clinicians were grabbing at straws, provided lessons for today, said researchers who reviewed the history of the epidemic -- now in its 25th year -- at the 16th International AIDS Conference here.

NANTES, France --The seventh trial of adjuvant Navelbine (vinorelbine)-Platinol (cisplatin) tips the balance toward improved survival in patients with stage IB to IIIA non-small-cell lung cancer (NSCLC).

TORONTO -- The target of most HIV therapy is the virus itself, but researchers said here that another approach -- blocking cells' entry points and locking the virus out -- is also starting to show promise.

TORONTO -- An investigational pediatric version of a recently approved HIV drug is safe and well-tolerated at two different doses and appears to be effective, researchers said here.